Background The present study aimed to evaluate the prescribing pattern and to assess the therapeutic outcome in the management of Benign Prostatic hyperplasia using IPSS and to provide a best treatment option for management of BPH. Methodology It is prospective observational study, 80 patients ≥50 years with BPH and treated with alpha- 1 blockers and 5-alpha reductase inhibitors were included in our study. The materials we used in our study include Informed consent form, Patient data collection form, and International Prostate Symptom Score. Results In IPSS follow up, we got mean baseline IPSS as 13.18 out of 35 and the mean follow up IPSS as 5.18. It shows that there is significant reduction of symptoms. We got mean difference of monotherapy and combination therapy as 7 and 8. Results with p<0.05 were considered as significant. Conclusion The therapeutic outcomes in evaluating treatment benefits in patients with LUTS/BPH were improvement in subjective symptoms and quality of life. Long term adherence to the medications resulted in decrease in bothersome LUTS. Based on mean difference obtained in our results, we conclude that combination therapy is bit more effective than monotherapy